Tags

Type your tag names separated by a space and hit enter

Cannabis use and premorbid functioning as predictors of poorer neurocognition in schizophrenia spectrum disorder.
Schizophr Res 2013; 143(1):84-9SR

Abstract

BACKGROUND

Evidence of associations between neurocognitive function and cannabis use in schizophrenia is inconclusive. However, direct measures of cannabis intake and premorbid function are rarely explored in this context. We investigated the relation between cannabis use, determined by its presence in urine, and neurocognitive functioning in schizophrenia controlling for the potential bias of premorbid functioning.

METHODS

Naturalistic study of 364 patients with schizophrenia spectrum disorder from catchment areas in Oslo, Norway. Hierarchical multiple regression analyses were used to assess the relationship between cannabis in urine and measures of neurocognitive functioning, with adjustment for confounders, including premorbid functioning.

RESULTS

Cannabis was detected in the urine of 21 patients, who had significant dysfunction in several neurocognitive domains independent of a current diagnosis of cannabis abuse. However, level of premorbid functioning explained the associations for all measures.

CONCLUSION

Differences in premorbid functioning may explain apparent differences in neurocognitive function between schizophrenia spectrum patients using cannabis or not. The findings suggest that illness-related traits present early in life can affect both later cannabis use and neurocognition, probably by complex mechanisms.

Authors+Show Affiliations

KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital, N-0424 Oslo, Norway. p.a.ringen@medisin.uio.noNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23178107

Citation

Ringen, P Andreas, et al. "Cannabis Use and Premorbid Functioning as Predictors of Poorer Neurocognition in Schizophrenia Spectrum Disorder." Schizophrenia Research, vol. 143, no. 1, 2013, pp. 84-9.
Ringen PA, Melle I, Berg AO, et al. Cannabis use and premorbid functioning as predictors of poorer neurocognition in schizophrenia spectrum disorder. Schizophr Res. 2013;143(1):84-9.
Ringen, P. A., Melle, I., Berg, A. O., Agartz, I., Spigset, O., Simonsen, C., ... Andreassen, O. A. (2013). Cannabis use and premorbid functioning as predictors of poorer neurocognition in schizophrenia spectrum disorder. Schizophrenia Research, 143(1), pp. 84-9. doi:10.1016/j.schres.2012.10.021.
Ringen PA, et al. Cannabis Use and Premorbid Functioning as Predictors of Poorer Neurocognition in Schizophrenia Spectrum Disorder. Schizophr Res. 2013;143(1):84-9. PubMed PMID: 23178107.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cannabis use and premorbid functioning as predictors of poorer neurocognition in schizophrenia spectrum disorder. AU - Ringen,P Andreas, AU - Melle,Ingrid, AU - Berg,Akiah O, AU - Agartz,Ingrid, AU - Spigset,Olav, AU - Simonsen,Carmen, AU - Sundet,Kjetil, AU - Andreassen,Ole A, Y1 - 2012/11/22/ PY - 2011/12/23/received PY - 2012/09/30/revised PY - 2012/10/27/accepted PY - 2012/11/27/entrez PY - 2012/11/28/pubmed PY - 2013/7/3/medline SP - 84 EP - 9 JF - Schizophrenia research JO - Schizophr. Res. VL - 143 IS - 1 N2 - BACKGROUND: Evidence of associations between neurocognitive function and cannabis use in schizophrenia is inconclusive. However, direct measures of cannabis intake and premorbid function are rarely explored in this context. We investigated the relation between cannabis use, determined by its presence in urine, and neurocognitive functioning in schizophrenia controlling for the potential bias of premorbid functioning. METHODS: Naturalistic study of 364 patients with schizophrenia spectrum disorder from catchment areas in Oslo, Norway. Hierarchical multiple regression analyses were used to assess the relationship between cannabis in urine and measures of neurocognitive functioning, with adjustment for confounders, including premorbid functioning. RESULTS: Cannabis was detected in the urine of 21 patients, who had significant dysfunction in several neurocognitive domains independent of a current diagnosis of cannabis abuse. However, level of premorbid functioning explained the associations for all measures. CONCLUSION: Differences in premorbid functioning may explain apparent differences in neurocognitive function between schizophrenia spectrum patients using cannabis or not. The findings suggest that illness-related traits present early in life can affect both later cannabis use and neurocognition, probably by complex mechanisms. SN - 1573-2509 UR - https://www.unboundmedicine.com/medline/citation/23178107/Cannabis_use_and_premorbid_functioning_as_predictors_of_poorer_neurocognition_in_schizophrenia_spectrum_disorder_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0920-9964(12)00593-2 DB - PRIME DP - Unbound Medicine ER -